• If this is your first visit, be sure to check out the FAQ & read the forum rules. To view all forums, post or create a new thread, you must be an AAPC Member. If you are a member and have already registered for member area and forum access, you can log in by clicking here. If you've forgotten the password it can be reset on our sign in section by entering your registered Email Address or Username here. To start viewing messages, select the forum that you want to visit from the selection below..

Wiki Z51.11 Help!

Create Wiki
J

johnsda@gritman.org

New
Messages
2
Location
Moscow, ID
Best answers
0
I'm trying to solve a disagreement between coding companies. Is Z51.11 an appropriate code for an encounter solely for growth factor administration when the growth factor is given as a supportive drug for an antineoplastic regimen given three days earlier? One place says it's not appropriate because the encounter itself isn't for an antineoplastic chemo drug. The other says it is because it is necessary part of the antineoplastic treatment as a whole, regardless of when the encounter occurred.
 
The Z51.1* are only for the visit where a J9*** drug is administered.

According to the ICD guidelines, Section I.C.2.e.2, when other services integral to the antineoplastic treatment are performed (brachytherapy), you still don't assign Z51.0. The same logic applies to non-chemotherapy drugs integral to the chemotherapy regimen.

2) Patient admission/encounter solely for administration of antineoplastic chemotherapy, immunotherapy and radiation therapy

If a patient admission/encounter is solely for the administration of chemotherapy, immunotherapy or external beam radiation therapy for the treatment of a neoplasm, assign code assign code Z51.0, Encounter for antineoplastic radiation therapy, or Z51.11, Encounter for antineoplastic chemotherapy, or Z51.12, Encounter for antineoplastic immunotherapy as the first-listed or principal diagnosis. If the reason for the encounter is more than one type of antineoplastic therapy, code Z51.0 and codes from subcategory Z51.1 may be assigned together, in which case one of these codes would be reported as a secondary diagnosis.

The malignancy for which the therapy is being administered should be assigned as a secondary diagnosis.

If a patient admission/encounter is for the insertion or implantation of radioactive elements (e.g., brachytherapy) the appropriate code for the malignancy is sequenced as the principal or first-listed diagnosis. Code Z51.0 should not be assigned.
Click to expand...

Per Noridian Medicare,
Administration of anti-anemia drugs and anti-emetic drugs by injection or infusion for cancer patients is not considered chemotherapy administration.
Click to expand...
https://med.noridianmedicare.com/we...dling-and-unbundling-of-services-and-supplies
(check your CMS MAC if it's a different one)

I would ask the company that is telling you to use Z51.11 if they have a reference or resource they can provide that supports their view that a G-CSF injection is "administration of chemotherapy."
 
Z29.89 is if it is used for G-CSF which means this "G-CSF is a drug that increases white blood cells (neutrophils) that protect you from infection. It’s most often used with chemotherapy and stem cell transplants." Johnsda Query sounds like growth factors which would be more under the Z17 Estrogen and other hormones and factors receptor status, which is for HER2 cancer growth factors in ICD-10-CM book . That questions need for clarification. Cannot guess when it comes to cancer. Must be specific. But check Z17 - codes
 
johnsda@gritman.org said:
Would Z29.89 be appropriate for G-CSF administrations in this case?
Click to expand...
The correct code for G-CSF is neutropenia, D70.*.

If the patient does not have neutropenia and is receiving G-CSF prophylactically, use the reason the provider feels the patient's white blood stores are at risk, along with the prophylactic drug code.

For example, a breast cancer patient receiving carboplatin and prophylactic Neulasta would be C50.919, Z79.630, and Z79.899.
 
dparham said:
Z29.89 is if it is used for G-CSF which means this "G-CSF is a drug that increases white blood cells (neutrophils) that protect you from infection. It’s most often used with chemotherapy and stem cell transplants." Johnsda Query sounds like growth factors which would be more under the Z17 Estrogen and other hormones and factors receptor status, which is for HER2 cancer growth factors in ICD-10-CM book . That questions need for clarification. Cannot guess when it comes to cancer. Must be specific. But check Z17 - codes
Click to expand...
I am having difficulty trying to parse what you are saying here, but Z17 is NOT correct for G-CSF.

Z17.* codes are for the hormone receptor status (ER, PR, HER2) of breast cancers. They have no bearing on the patient's white blood count or need for G-CSF.

See my other comment for the correct dx coding for G-CSF drugs.
 
Tracy, I was just looking for something else and saw your comment. I did not say the person should use those codes. I said I would query the provider if it is not clarified in the visit note. I would love to know how you came up with the codes you have, e.g. C50.919 is for a female patient. The Neulasta is probably to prevent infection caused by chemo for an active breast cancer, but male and female can have breast cancer. Email me direct at medss@comcast.net if you see this. I believe proper documentation is needed and we have to read entire note so we are not guessing :)
 
You must log in or register to reply here.
Top